SequelSEC

ZEVRA THERAPEUTICS, INC. ZVRA

Pharmaceutical Preparations · CIK 0001434647 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$136.07M
Fiscal year ended 2026-06-30
Operating income
$82.38M
Fiscal year ended 2026-06-30
Free cash flow
$32.62M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$454.80MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$7.75Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income5.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue4.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin78.2%97th
Revenue YoY growth350.9%90th
FCF margin-2.3%70th
Effective tax rate4.0%32th
Operating margin-59.1%65th
CapEx / revenue0.8%36th
Current ratio5.68x64th
SBC / revenue11.9%39th
Long-term debt / equity0.40x43th

ZEVRA THERAPEUTICS, INC. (ZVRA) reported revenue of $136.07M and net income of $58.26M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ZEVRA THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ZEVRA THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$136.07M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$82.38M
Net income$58.26M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income$69.29M
Income tax expense$11.02M
Diluted EPSUnavailable
Selling, general & administrative$74.63M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

ZEVRA THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$145.32M
Total assets$302.71M
Current assets$251.30M
Total liabilities$85.06M
Current liabilities$48.63M
Total equity incl. NCI$217.65M
Temporary (mezzanine) equityUnavailable
Inventory$2.45M
Accounts receivableUnavailable
Goodwill$4.70M
Long-term debt$0
Accounts payableUnavailable

Cash flow

ZEVRA THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$33.40M
Capital expenditures$775.00K
Investing cash flow$106.72M
Financing cash flow-$42.14M
Net change in cash$97.61M
Stock-based compensation$13.13M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$1.49M

Derived

ZEVRA THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$32.62M
Gross marginUnavailable
Operating margin60.5%
FCF margin24.0%
SBC / revenue9.6%
Current ratio5.17x
Revenue YoY growth119.4%
Net margin42.8%
R&D / revenueUnavailable
CapEx / revenue0.6%
Long-term debt / equity0.00x
Effective tax rate15.9%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZVRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.